# ACADIA PHARMACEUTICALS INC. (ACAD) FY2026 Q2 Balance Sheet

- Company: ACADIA PHARMACEUTICALS INC. (ACAD)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001193125-26-333243
- Page: https://plicit.ai/financials/acad/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/acad-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,742,900,000 US dollars
- **Current assets**: 1,224,545,000 US dollars
- **Non-current assets**: 518,355,000 US dollars
- **Liabilities**: 436,291,000 US dollars
- **Current liabilities**: 361,436,000 US dollars
- **Non-current liabilities**: 74,855,000 US dollars
- **Equity**: 1,306,609,000 US dollars
- **Investment securities, available-for-sale**: 571,489,000 US dollars
- **Cash and cash equivalents**: 384,985,000 US dollars
- **Accounts receivable, net**: 150,642,000 US dollars
- **Prepaid expenses and other current assets**: 69,369,000 US dollars
- **Inventory**: 32,372,000 US dollars
- **Interest and other receivables**: 15,688,000 US dollars
- **Deferred tax assets**: 240,679,000 US dollars
- **Intangible assets, net**: 103,448,000 US dollars
- **Long-term inventory**: 76,301,000 US dollars
- **Operating lease right-of-use assets**: 69,424,000 US dollars
- **Property and equipment, net**: 17,107,000 US dollars
- **Restricted cash**: 7,846,000 US dollars
- **Other assets**: 3,550,000 US dollars
- **Accrued liabilities**: 316,870,000 US dollars
- **Accounts payable**: 44,566,000 US dollars
- **Operating lease liabilities**: 59,547,000 US dollars
- **Other long-term liabilities**: 15,308,000 US dollars
- **Additional paid-in capital**: 3,085,800,000 US dollars
- **Common stock, $0.0001 par value; 225,000,000 shares authorized at June 30, 2026 and December 31, 2025; 172,132,442 shares and 170,309,376 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively**: 16,000 US dollars
- **Preferred stock, $0.0001 par value; 5,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025**: 0 US dollars
- **Accumulated deficit**: negative 1,778,249,000 US dollars
- **Accumulated other comprehensive (loss) income**: negative 958,000 US dollars
- **Gross equity (calculated)**: 3,085,816,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.